MDGL

SEC source: 0001628280-25-012826 · wk-form4_1741983899.xml · derivative · entry 20

CRAVES FRED B · CIK 0001014095 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,742

Underlying: Common Stock · 1,728 shares

Expires 2025-06-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F16 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable.

SEC source: 0001628280-25-012826 · wk-form4_1741983899.xml · nonDerivative · entry 7

CRAVES FRED B · CIK 0001014095 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 350,076

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $334.95 to $334.99, inclusive.

SEC source: 0001628280-25-012826 · wk-form4_1741983899.xml · nonDerivative · entry 6

CRAVES FRED B · CIK 0001014095 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 350,276

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $333.39 to $333.89, inclusive.

SEC source: 0001628280-25-012826 · wk-form4_1741983899.xml · nonDerivative · entry 5

CRAVES FRED B · CIK 0001014095 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 351,076

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $332.01 to $332.88, inclusive.

SEC source: 0001628280-25-012826 · wk-form4_1741983899.xml · nonDerivative · entry 4

CRAVES FRED B · CIK 0001014095 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 353,458

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $331.00 to $331.89, inclusive.

SEC source: 0001628280-25-012826 · wk-form4_1741983899.xml · nonDerivative · entry 3

CRAVES FRED B · CIK 0001014095 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 356,217

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $330.00 to $330.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.

SEC source: 0001628280-25-012826 · wk-form4_1741983899.xml · nonDerivative · entry 2

CRAVES FRED B · CIK 0001014095 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 357,804

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001628280-25-012826 · wk-form4_1741983899.xml · nonDerivative · entry 1

CRAVES FRED B · CIK 0001014095 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 351,804

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001628280-25-012364 · wk-form4_1741811339.xml · derivative · entry 2

FOUSE JACQUALYN A · CIK 0001405288 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,579

Underlying: Common Stock · 1,579 shares

Expires 2035-03-10

F2 · derivative.exercise_date: The option vests as to 50% of the shares on the first anniversary of the date of grant (March 10, 2026) and, thereafter, 12.5% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.

SEC source: 0001628280-25-012364 · wk-form4_1741811339.xml · nonDerivative · entry 1

FOUSE JACQUALYN A · CIK 0001405288 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 894

F1 · kind: Represents a grant of restricted stock units, which vest as to 50% of the shares on each of March 10, 2026 and March 10, 2027, provided the Reporting Person continues in service with the Issuer on each such date.

SEC source: 0001628280-25-012369 · wk-form4_1741811523.xml · nonDerivative · entry 1

Dier Mardi · CIK 0001574591 · SVP and CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,440

F1 · kind: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2024.

SEC source: 0001628280-25-011410 · wk-form4_1741387671.xml · derivative · entry 2

Sibold William John · CIK 0001518611 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,009

Underlying: Common Stock · 22,009 shares

Expires 2035-03-05

F2 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (March 5, 2026) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.

SEC source: 0001628280-25-011410 · wk-form4_1741387671.xml · nonDerivative · entry 1

Sibold William John · CIK 0001518611 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 117,369

F1 · kind: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 5, 2026, March 5, 2027, March 5, 2028 and March 5, 2029, provided the Reporting Person continues in service with the Issuer on each such date.

SEC source: 0001628280-25-011407 · wk-form4_1741387433.xml · derivative · entry 2

Dier Mardi · CIK 0001574591 · SVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,374

Underlying: Common Stock · 6,374 shares

Expires 2035-03-05

F2 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (March 5, 2026) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.

SEC source: 0001628280-25-011407 · wk-form4_1741387433.xml · nonDerivative · entry 1

Dier Mardi · CIK 0001574591 · SVP and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,698

F1 · kind: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 5, 2026, March 5, 2027, March 5, 2028 and March 5, 2029, provided the Reporting Person continues in service with the Issuer on each such date.

SEC source: 0001628280-25-011405 · wk-form4_1741387197.xml · derivative · entry 15

Waltermire Robert E. · CIK 0001876996 · Senior VP, Chief Pharma Dev.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,157

Underlying: Common Stock · 1,157 shares

Expires 2035-03-05

F13 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (March 5, 2026) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.

SEC source: 0001628280-25-011405 · wk-form4_1741387197.xml · derivative · entry 14

Waltermire Robert E. · CIK 0001876996 · Senior VP, Chief Pharma Dev.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,062

Underlying: Common Stock · 7,288 shares

Expires 2032-02-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F12 · derivative.exercise_date: All shares issued pursuant to the exercise of the options reported herein represent 7,288 shares underlying an overall option award of 12,250 shares. All exercised options had vested. As to the overall option for 12,250 shares, 25% of the shares underlying the option vested on February 24, 2023 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.

SEC source: 0001628280-25-011405 · wk-form4_1741387197.xml · derivative · entry 13

Waltermire Robert E. · CIK 0001876996 · Senior VP, Chief Pharma Dev.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,375

Underlying: Common Stock · 6,825 shares

Expires 2031-08-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F11 · derivative.exercise_date: All shares issued pursuant to the exercise of the options reported herein represent 6,825 shares underlying an overall option award of 35,000 shares. All exercised options had vested. As to the overall option for 35,000 shares, 25% of the shares underlying the option vested on August 2, 2022 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.

SEC source: 0001628280-25-011405 · wk-form4_1741387197.xml · nonDerivative · entry 12

Waltermire Robert E. · CIK 0001876996 · Senior VP, Chief Pharma Dev.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,789

F10 · kind: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 5, 2026, March 5, 2027, March 5, 2028 and March 5, 2029, provided the Reporting Person continues in service with the Issuer on each such date.

SEC source: 0001628280-25-011405 · wk-form4_1741387197.xml · nonDerivative · entry 11

Waltermire Robert E. · CIK 0001876996 · Senior VP, Chief Pharma Dev.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,728

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $344.31 to $345.07, inclusive.

SEC source: 0001628280-25-011405 · wk-form4_1741387197.xml · nonDerivative · entry 10

Waltermire Robert E. · CIK 0001876996 · Senior VP, Chief Pharma Dev.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,140

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $343.31 to $344.30, inclusive.

SEC source: 0001628280-25-011405 · wk-form4_1741387197.xml · nonDerivative · entry 9

Waltermire Robert E. · CIK 0001876996 · Senior VP, Chief Pharma Dev.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,841

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $342.30 to $343.29, inclusive.

SEC source: 0001628280-25-011405 · wk-form4_1741387197.xml · nonDerivative · entry 8

Waltermire Robert E. · CIK 0001876996 · Senior VP, Chief Pharma Dev.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,918

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $341.24 to $342.05, inclusive.

SEC source: 0001628280-25-011405 · wk-form4_1741387197.xml · nonDerivative · entry 7

Waltermire Robert E. · CIK 0001876996 · Senior VP, Chief Pharma Dev.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,961

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $340.24 to $341.18, inclusive.

SEC source: 0001628280-25-011405 · wk-form4_1741387197.xml · nonDerivative · entry 6

Waltermire Robert E. · CIK 0001876996 · Senior VP, Chief Pharma Dev.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,618

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $339.21 to $340.14, inclusive.

SEC source: 0001628280-25-011405 · wk-form4_1741387197.xml · nonDerivative · entry 5

Waltermire Robert E. · CIK 0001876996 · Senior VP, Chief Pharma Dev.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,018

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $337.47 to $338.44, inclusive.

SEC source: 0001628280-25-011405 · wk-form4_1741387197.xml · nonDerivative · entry 4

Waltermire Robert E. · CIK 0001876996 · Senior VP, Chief Pharma Dev.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,164

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $336.445 to $337.44, inclusive.

SEC source: 0001628280-25-011405 · wk-form4_1741387197.xml · nonDerivative · entry 3

Waltermire Robert E. · CIK 0001876996 · Senior VP, Chief Pharma Dev.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,941

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $335.005 to $335.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.

SEC source: 0001628280-25-011405 · wk-form4_1741387197.xml · nonDerivative · entry 2

Waltermire Robert E. · CIK 0001876996 · Senior VP, Chief Pharma Dev.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,841

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001628280-25-011405 · wk-form4_1741387197.xml · nonDerivative · entry 1

Waltermire Robert E. · CIK 0001876996 · Senior VP, Chief Pharma Dev.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,553

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001628280-25-011359 · wk-form4_1741384821.xml · derivative · entry 3

Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,381

Underlying: Common Stock · 7,381 shares

Expires 2035-03-05

F3 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (March 5, 2026) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.

SEC source: 0001628280-25-011359 · wk-form4_1741384821.xml · nonDerivative · entry 1

Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 461,044

F1 · kind: 1. Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 5, 2026, March 5, 2027, March 5, 2028 and March 5, 2029, provided the Reporting Person continues in service with the Issuer on each such date.

SEC source: 0001628280-25-011354 · wk-form4_1741384239.xml · derivative · entry 2

Kelley Shannon T · CIK 0002034056 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,368

Underlying: Common Stock · 5,368 shares

Expires 2035-03-05

F2 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (March 5, 2026) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.

SEC source: 0001628280-25-011354 · wk-form4_1741384239.xml · nonDerivative · entry 1

Kelley Shannon T · CIK 0002034056 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,477

F1 · kind: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 5, 2026, March 5, 2027, March 5, 2028 and March 5, 2029, provided the Reporting Person continues in service with the Issuer on each such date.

SEC source: 0001628280-25-011321 · wk-form4_1741383098.xml · derivative · entry 2

Huntsman Carole · CIK 0002001571 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,703

Underlying: Common Stock · 5,703 shares

Expires 2035-03-05

F2 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (March 5, 2026) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.

SEC source: 0001628280-25-011321 · wk-form4_1741383098.xml · nonDerivative · entry 1

Huntsman Carole · CIK 0002001571 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,990

F1 · kind: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 5, 2026, March 5, 2027, March 5, 2028 and March 5, 2029, provided the Reporting Person continues in service with the Issuer on each such date.

SEC source: 0001628280-25-010510 · wk-form4_1741210575.xml · nonDerivative · entry 1

Kelley Shannon T · CIK 0002034056 · General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,290

F1 · kind: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2024.

SEC source: 0001628280-25-010508 · wk-form4_1741210303.xml · nonDerivative · entry 2

Dier Mardi · CIK 0001574591 · SVP and CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,914

F2 · kind: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2024.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $323.38 to $323.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001628280-25-010508 · wk-form4_1741210303.xml · nonDerivative · entry 1

Dier Mardi · CIK 0001574591 · SVP and CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,688

F1 · kind: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.

SEC source: 0001628280-25-010492 · wk-form4_1741209863.xml · nonDerivative · entry 9

Huntsman Carole · CIK 0002001571 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,604

F1 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

SEC source: 0001628280-25-010492 · wk-form4_1741209863.xml · nonDerivative · entry 8

Huntsman Carole · CIK 0002001571 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,167

F1 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

SEC source: 0001628280-25-010492 · wk-form4_1741209863.xml · nonDerivative · entry 7

Huntsman Carole · CIK 0002001571 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,267

F1 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

SEC source: 0001628280-25-010492 · wk-form4_1741209863.xml · nonDerivative · entry 6

Huntsman Carole · CIK 0002001571 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,367

F1 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

SEC source: 0001628280-25-010492 · wk-form4_1741209863.xml · nonDerivative · entry 5

Huntsman Carole · CIK 0002001571 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,467

F1 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $324.48 to $324.70, inclusive.

SEC source: 0001628280-25-010492 · wk-form4_1741209863.xml · nonDerivative · entry 4

Huntsman Carole · CIK 0002001571 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,667

F1 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $323.47 to $323.83, inclusive.

SEC source: 0001628280-25-010492 · wk-form4_1741209863.xml · nonDerivative · entry 3

Huntsman Carole · CIK 0002001571 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,867

F1 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $320.13 to $320.32, inclusive.

SEC source: 0001628280-25-010492 · wk-form4_1741209863.xml · nonDerivative · entry 2

Huntsman Carole · CIK 0002001571 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,167

F1 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $314.40 to $315.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.

SEC source: 0001628280-25-010492 · wk-form4_1741209863.xml · nonDerivative · entry 1

Huntsman Carole · CIK 0002001571 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,367

F1 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

SEC source: 0001628280-25-010224 · wk-form4_1741141462.xml · nonDerivative · entry 2

Waltermire Robert E. · CIK 0001876996 · Senior VP, Chief Pharma Dev.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,728

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $341.52 to $341.57, inclusive.

SEC source: 0001628280-25-010224 · wk-form4_1741141462.xml · nonDerivative · entry 1

Waltermire Robert E. · CIK 0001876996 · Senior VP, Chief Pharma Dev.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,903

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $340.495 to $341.415, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnote below.